Bill Ackman Eyes New Fund to Bet Against Market Complacency 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
TEL AVIV, Israel, Nov. 07, 2016 -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that management will participate in several upcoming investor healthcare conferences.
| Stifel Healthcare Conference | |
| Date: | Tuesday, November 15 |
| Time: | 4:30PM EST |
| Location: | The Lotte New York Palace Hotel |
| Jefferies London Healthcare Conference | |
| Date: | Thursday, November 17 |
| Time: | 09:20AM GMT |
| Location: | Waldorf Hilton, London, United Kingdom |
| Webcast: | http://wsw.com/webcast/jeff100/adhd |
| 28th Annual Piper Jaffray Healthcare Conference | |
| Date: | Tuesday, November 29 |
| Time: | 10:00AM EST |
| Panel Title: | Underdiscovered Neuro-Innovators Panel |
| Location: | The Lotte New York Palace Hotel |
| Oppenheimer Life Sciences Summit | |
| Date: | Tuesday, November 29 |
| Location: | The Sofitel New York Hotel |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of MDX (Metadoxine Extended Release), a proprietary drug candidate to treat cognitive disorders including ADHD and Fragile X Syndrome. For more information, please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.
U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 [email protected] Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 [email protected] Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661 [email protected]
